Last June, Vermont became the first state in the country to pass a law requiring drug makers to justify their price hikes. The move, which was opposed by the pharmaceutical industry, was borne out of frustration that the federal government had not acted on the rising cost of prescription medicines. But the law has its limits, as indicated by the first report by the state attorney general, which was issued last month. Confidential data will not be publicly released and the state has no power to do anything about prices, other than issue $10,000 fines to companies that fail to comply. We spoke with Chris Pearson, a Vermont legislator who was vice chair of the House Committee on Health Care and championed the bill, about the results and where this is headed. This is an edited version of our conversation …

Pharmalot: What was the hope when you pushed for this law?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy